Carcinogenicity Studies: Market Size & Forecast 2026

The global carcinogenicity studies market is valued at USD 2.8 billion in 2025, representing a critical component of pharmaceutical R&D & clinical services with 7.2% projected CAGR through 2032. The market sits in a structurally tight balance between traditional 2-year rodent carcinogenicity studies and emerging alternative models, driven by evolving ICH guidelines, increasing oncology pipelines, and a transition toward weight-of-evidence approaches that reduce reliance on animal testing. > **Analyst Take.** Our view: the ICH S1B(R1) addendum represents a structural inflection point that procurement teams are underpricing. While 2-year rodent studies remain the gold standard for high-concern oncology compounds, the ability to leverage WoE approaches could reduce development costs by $1.2-2.4M per study for approximately 40% of oncology candidates. Buyers should position now for this tran

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.